En Plus One Biosciences announced it raised $11.9 Million in an initial filing from an offering of $12.4 Million

Company

Location

About

EnPlusOne is enabling the future of RNA therapeutics. Its ezRNA™ platform is a revolutionary innovation that harnesses the power of enzymes to synthesize RNA and can incorporate a diverse array of natural and modified nucleotides. Their enzymatic, water-based approach promises to unlock sustainable and scalable commercial manufacturing of RNA therapeutics.